4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Medios AG (ILM1) operates in the Medical Distribution industry and is headquartered in Berlin, Germany with about 868 employees. Its market capitalization is roughly €290 million. In the fiscal year ended 2025-12-31, ILM1 reported €2.1B in revenue and €15M in net income.
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | €2.1B | €1.9B | €1.8B | €1.6B |
| Gross Profit | €199M | €152M | €110M | €107M |
| Operating Income (EBIT) | €42M | €30M | €31M | €27M |
| Net Income | €15M | €12M | €19M | €18M |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | €528M | €549M | €538M | €507M | €485M |
| Gross Profit | €50M | €51M | €50M | €51M | €48M |
| Operating Income (EBIT) | €10M | €10M | €11M | €11M | €10M |
| Net Income | €5M | (€4M) | €7M | €6M | €6M |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | €903M | €934M | €595M | €576M | — |
| Total Liabilities | €389M | €424M | €126M | €128M | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ILM1 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms